# US 2023/0410942 A1 · Use of non-error-propagating phasing techniques and combination of allelic balance to improve cnv detection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0410942 A1
- Document ID: US20230410942A1
- Status: Published application
- Kind: A1
- Application number: 18/251,096
- Filed: 2021-10-29
- Published: 2023-12-21
- Earliest claimed: 2020-10-30
- Assignees: Myome, Inc.
- Applicants: Myome, Inc.
- Inventors: AKASH KUMAR; MATTHEW RABINOWITZ
- Web page: https://patentgrep.com/patent/US20230410942A1

## CPC

- G16B 30/10: Sequence alignment; Homology search
- G16B 20/10: Ploidy or copy number detection
- C12Q 1/6869: Methods for sequencing
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein are methods of using non-error-propagating phasing techniques in combination with sequencing data obtained through more conventional error-propagating approaches to improve phasing of a genome and correct allele balance signals, which may allow for improved determinations of ploidy status of chromosomal segments. Further disclosed herein are methods of using allele balance and depth of read in combination to make improved ploidy status determinations. The techniques described herein may be used in a minimally invasive manner to make ploidy status determinations for an embryo or fetus and to identify chromosomal instability in tumor DNA.

## Claims

### Claim 1

A method of correcting an allele balance signal for a chromosomal segment, the method comprising:
obtaining a reference genetic code comprising two phase sets, each phase set having one or more variants of interest, optionally wherein the reference genetic code is at least partially phased;
obtaining the allele balance signal for the one or more variants of interest from sequencing performed on a sample of genetic material;
obtaining a plurality of reads sequenced using a non-error-propagating technique, wherein each read comprises at least one of the one or more variants of interest;
determining the phase alignment of the two phase sets as being in phase or out of phase based on the plurality of reads; and
determining a true allele balance signal by confirming, correcting, or supplying the phasing of at least one variant of interest based on the determined phase alignment of the two phase sets.

### Claim 2 (depends on 1)

The method of claim 1, wherein the non-error-propagating technique comprises chromosome conformation capture, single-cell template strand sequencing, or chromosomal isolation (e.g., via laser capture microdissection or karyotype).

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, further comprising performing the non-error-propagating technique to obtain the plurality of reads.

### Claim 4

The method of any one of the preceding claims, wherein obtaining the allele balance signal comprises performing the sequencing on the sample of genetic material.

### Claim 5

The method of any one of the preceding claims, wherein the allele balance signal and the plurality of reads are derived from the same sample of genetic material, optionally wherein the sample is a body fluid sample (e.g., a blood sample, a saliva sample) or a tissue biopsy sample, further optionally wherein the allele balance signal and the plurality of reads are derived from a same population of cells.

### Claim 6

The method of any one of the preceding claims, wherein the allele balance signal is derived from cell-free DNA and the plurality of reads are derived from cellular DNA, optionally wherein the cellular DNA is from cells found within a body fluid (e.g., blood or saliva).

### Claim 7

The method of any one of the preceding claims, wherein the reference genetic code is derived from the sequencing used to generate the allele balance signal.

### Claim 8

The method of any one of the preceding claims, wherein the reference genetic code is derived, at least in part, from sequencing of normal tissue in a subject for which the allele balance signal is obtained.

### Claim 9

The method of any one of the preceding claims, wherein the reference genetic code is derived, at least in part, from sequencing of germline tissue in a subject for which the allele balance signal is obtained.

### Claim 10

The method of any one of the preceding claims, wherein the reference genetic code is derived, at least in part, from sequencing genetic material from one or more genetic relatives of a subject for which the allele balance signal is obtained.

### Claim 11 (depends on 10)

The method of claim 10, wherein the one or more relatives is a mother and/or a father.

### Claim 12 (depends on 10, 11)

The method of claim 10 or 11, wherein the reference genetic code is derived, at least in part, from germline sequencing of the one or genetic relatives.

### Claim 13

The method of any one of the preceding claims, wherein the reference genetic code is derived, at least in part, from whole genome shotgun sequencing of a subject for which the allele balance signal is obtained.

### Claim 14 (depends on 13)

The method of claim 13, wherein the allele balance signal is derived from the whole genome shotgun sequencing.

### Claim 15 (depends on 13, 14)

The method of claim 13 or 14, wherein the whole genome shotgun sequencing is performed on cell-free DNA in a body fluid sample (e.g., a blood sample or saliva sample).

### Claim 16

The method of any one of the preceding claims, wherein the non-error-propagating technique comprises single cell sequencing.

### Claim 17

The method of any one of the preceding claims, further comprising collecting a sample of genetic material from which the allele balance signal is derived.

### Claim 18

The method of any one of the preceding claims, further comprising collecting a sample of genetic material from which the plurality of reads are derived.

### Claim 19

The method of any one of the preceding claims, wherein correcting the allele balance data comprises correcting a switch error in the at least partially phased reference genetic code.

### Claim 20

The method of any one of the preceding claims, wherein the allele balance signal is averaged over a plurality of binned variants within a region of at least about 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, 750,000, 1,000,000, 50,000,000, or 100,000,000 bp.

### Claim 21

The method of any one of the preceding claims, wherein the allele balance signal is averaged over a plurality of binned variants within a region of no greater than about 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, 750,000, 1,000,000, 50,000,000, or 100,000,000 bp.

### Claim 22

The method of any one of the preceding claims, wherein the allele balance is averaged over a haplotype block.

### Claim 23 (depends on 22)

The method of claim 22, wherein the haplotype block was determined by dilution pool sequencing, optionally wherein the allele balance signal was derived from the same sequencing.

### Claim 24

The method of any one of the preceding claims, wherein the allele balance signal is filtered for a minimum read depth, optionally wherein the minimum read depth is 5, 10, 15, 20, or 25 reads.

### Claim 25

The method of any one of the preceding claims, wherein the two phase sets are neighboring phase sets within the reference genetic code.

### Claim 26 (depends on 25)

The method of claim 25, wherein each of the neighboring phase sets comprises a variant of interest which is no further than about 1,000, 5,000, 10,000, 50,000, 100,000, 500,0000, 1,000,000, 5,000,000, 10,000,000, 50,000,000, 100,000,000, or 250,000,000 bp from a variant of interest in the other.

### Claim 27

The method of any one of the preceding claims, wherein the plurality of reads are filtered for reads comprising at least 2, 3, 4, or 5 of the variants of interest from each of the two phase sets.

### Claim 28 (depends on 2)

The method of claim 2, wherein the non-error-propagating technique comprises chromosome conformation capture, optionally wherein the chromosome conformation capture is Hi-C.

### Claim 29 (depends on 28)

The method of claim 28, wherein determining the phase alignment based on the plurality of reads comprises determining whether most of the reads are concordant or discordant with respect to a presumed phasing alignment between the two phase sets, optionally wherein the presumed phasing alignment is based on the at least partial phasing of the reference genetic code.

### Claim 30 (depends on 28, 29)

The method of claim 28 or 29, wherein determining the phase alignment based on the plurality of reads comprises determining or estimating a probability that an amount of concordance or discordance observed between the two phase sets from the plurality of reads is the result of chance.

### Claim 31 (depends on 30)

The method of claim 30, wherein the probability is a binomial probability, optionally assuming that there is an equal chance than an observed fragment will be concordant or discordant.

### Claim 32

The method of any one of the preceding claims, further comprising using the corrected allele balance signal to determine a ploidy status for a chromosomal segment, optionally wherein determining the ploidy status comprises calling a copy number variant (CNV).

### Claim 33

A method of determining a ploidy status for a chromosomal segment, the method comprising:
obtaining a depth of read signal for a first set of one or more variants within the chromosomal segment;
obtaining an allele balance signal for a second set of one or more variants within the chromosomal segment; and
using the depth of read signal in combination with the allele balance signal to determine the ploidy status of the chromosomal segment.

### Claim 34 (depends on 33)

The method of claim 33, wherein determining the ploidy status of the chromosomal segment comprises determining whether or not a CNV exists within the chromosomal segment.

### Claim 35 (depends on 33, 34)

The method of claim 33 or 34, wherein obtaining the depth of read signal comprises obtaining a number of sequencing reads mapped to at least one of the variants within the first set normalized relative to a total number of reads.

### Claim 36 (depends on 33, 34, 35)

The method of any one of claims 33-35, wherein the depth of read signal is averaged over a binned plurality of variants within a region of at least about 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, 750,000, 1,000,000, 50,000,000, or 100,000,000 bp.

### Claim 37 (depends on 33, 34, 35, 36)

The method of any one of claims 33-36, wherein the depth of read signal is averaged over a binned plurality of variants within a region no greater than about 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, 750,000, 1,000,000, 50,000,000, or 100,000,000 bp.

### Claim 38 (depends on 33, 34, 35, 36, 37)

The method of any one of claims 33-37, wherein the depth of read signal is averaged over a haplotype block.

### Claim 39 (depends on 38)

The method of claim 38, wherein the haplotype block was determined by dilution pool sequencing.

### Claim 40 (depends on 33, 34, 35, 36, 37, 38)

The method of any one of claims 33-38, wherein the allele balance signal is averaged over a binned plurality of variants within a region of at least about 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, 750,000, 1,000,000, 50,000,000, or 100,000,000 bp.

### Claim 41 (depends on 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 33-40, wherein the allele balance signal is averaged over a binned plurality of variants within a region no greater than about 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, 750,000, 1,000,000, 50,000,000, or 100,000,000 bp.

### Claim 42 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 33-41, wherein the allele balance signal is averaged over a haplotype block.

### Claim 43 (depends on 42)

The method of claim 42, wherein the haplotype block was determined by dilution pool sequencing.

### Claim 44 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 33-43, wherein the depth of read signal and the allele balance signal are averaged over the same binned region.

### Claim 45 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 33-44, wherein using the depth of read signal in combination with the allele balance signal comprises making a positive or negative determination only when both the depth of read signal exceeds a depth of read threshold and the allele balance signal exceeds an allele balance threshold or when neither the depth of read signal exceeds the depth of read threshold nor the allele balance signal exceeds the allele balance threshold.

### Claim 46 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 33-44, wherein using the depth of read signal in combination with the allele balance signal comprises combining the depth of read signal and the allele balance signal into a single combined signal.

### Claim 47 (depends on 46)

The method of claim 46, wherein combining the depth of read signal and the allele balance signal into a single combined signal comprises multiplying the signals together.

### Claim 48 (depends on 46)

The method of claim 46, wherein combining the depth of read signal and the allele balance signal into a single combined signal comprises adding the signals together.

### Claim 49 (depends on 46, 47, 48)

The method of any one of claims 46-48, wherein the combined signal is averaged over a binned plurality of variants within a region of at least about 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, 750,000, 1,000,000, 50,000,000, or 100,000,000 bp.

### Claim 50 (depends on 46, 47, 48, 49)

The method of any one of claims 46-49, wherein the combined signal is averaged over a binned plurality of variants within a region no greater than about 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, 750,000, 1,000,000, 50,000,000, or 100,000,000 bp.

### Claim 51 (depends on 46, 47, 48, 49, 50)

The method of any one of claims 46-50, wherein the combined signal is averaged over a haplotype block.

### Claim 52 (depends on 51)

The method of claim 51, wherein the haplotype block was determined by dilution pool sequencing.

### Claim 53 (depends on 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 46-52, wherein the combined signal is averaged over a plurality of bins across which the depth of read signal and/or the allele balance signal were averaged.

### Claim 54 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 33-53, wherein the first set of one or more variants consists of 1 variant.

### Claim 55 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 33-53, wherein the first set of one or more variants comprises at least 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1,000 variants.

### Claim 56 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 33-55, wherein the second set of one or more variants consists of 1 variant.

### Claim 57 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 33-53, wherein the second set of one or more variants comprises at least 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1,000 variants.

### Claim 58 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 33-57, wherein the first set of one or more variants is identical to the second set of one or more variants.

### Claim 59 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 33-58, wherein obtaining the depth of read signal and/or obtaining the allele balance signal comprises performing sequencing.

### Claim 60 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 33-59, wherein the depth of read signal and allele balance signal are derived from the same sequencing data.

### Claim 61 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 33-60, wherein the depth of read signal and/or the allele balance signal is filtered for a minimum read depth, optionally wherein the minimum read depth is 5, 10, 15, 20, or 25 reads.

### Claim 62 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 33-61, further comprising calculating an individual probability of accurate determination of ploidy status based on the depth of read signal and/or the allele balance signal or calculating a joint probability of accurate determination of ploidy status based on the depth of read signal and the allele balance signal, optionally wherein the probabilities measure the probability of one of the following: a true positive, a false positive, a true negative, and a false negative.

### Claim 63 (depends on 62)

The method of claim 62, wherein at least one of the following is true:
a) the joint probability of a false positive is less than both of the individual probabilities of a false positive;
b) the joint probability of a false negative is less than both of the individual probabilities of a false negative;
c) the joint probability of a true positive is greater than both of the individual probabilities of a true positive; and
d) the joint probability of a true negative is greater than both of the individual probabilities of a true negative;

### Claim 64 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 33-63, wherein the depth of read signal is offset against a first baseline signal and/or the allele balance signal is offset against a second baseline signal.

### Claim 65 (depends on 64)

The method of claim 64, wherein each baseline signal is based on a mean signal for a second chromosomal segment having a known ploidy status, optionally wherein the second chromosomal segment having a known ploidy status is within the same chromosome as the chromosomal segment for which the ploidy status is being determined.

### Claim 66 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 33-65, wherein the depth of read signal and/or the allele balance signal is normalized against a measure of noise within the signal, optionally wherein the measure of noise is the standard deviation or variance of the signal over the chromosomal segment for which the ploidy status is being determined, over the second chromosomal segment of claim 65, over a third chromosomal segment having a known ploidy status of interest that is different from the ploidy status of the second chromosomal segment, or over the entire chromosome.

### Claim 67 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method any one of claims 33-66, wherein a variance in the depth of read signal and a variance within the allele balance signal are within 100, 90, 80, 70, 60, 50, 40, 30, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, or 1.1 fold of each other.

### Claim 68 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 33-67, wherein using the depth of read signal in combination with the allele balance signal results in reducing the false positive rate and/or the false negative rate by at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60 70, 80, 90, 100, 150, 200, 250, or 500 fold relative to the false positive rate and/or false negative rate obtained with using one or both of the signals individually.

### Claim 69 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 33-68, wherein using the depth of read signal in combination with the allele balance signal comprises selecting a depth of read threshold and an allele balance threshold, optionally wherein the signal thresholds are each half the mean value of respective signals averaged over a plurality of variants known to exhibit a ploidy status of interest (e.g., an aneuploidy).

### Claim 70 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any one of claims 33-69, wherein using the depth of read signal in combination with the allele balance signal comprises selecting a combined signal threshold, optionally wherein the combined signal threshold is half the mean value of a combined signal averaged over a plurality of variants known to exhibit a ploidy status of interest (e.g., an aneuploidy).

### Claim 71 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 33-70, wherein the method results in an aneuploidy of one or more chromosomes being detected.

### Claim 72 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 33-70, wherein the method results in euploidy of all chromosomes analyzed being detected.

### Claim 73 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any one of claims 33-72, wherein the method results in an addition and/or deletion of a chromosomal segment being detected.

### Claim 74 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 33-73, wherein the method results in a CNV being identified.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 33-74, wherein obtaining the allele balance signal comprises correcting an original allele balance signal by performing the method of any one of claims 1-32.

### Claim 76

The method of any one of the preceding claims, wherein the method comprises obtaining a signal indicative of ploidy status (e.g., the allele balance signal or depth of read signal) that is derived from a sample comprising a population of cells having different copy numbers for the chromosomal segment, optionally wherein some cells have an aneuploidy and others do not.

### Claim 77

The method of any one of the preceding claims, wherein the method comprises obtaining a signal indicative of ploidy status (e.g., the allele balance signal or depth of read signal) that is derived from a sample comprising one or more tumor cells.

### Claim 78 (depends on 77)

The method of claim 77, wherein the sample further comprises non-tumor cells.

### Claim 79

The method of any one of the preceding claims, wherein the method comprises obtaining a signal indicative of ploidy status (e.g., the allele balance signal or depth of read signal) that is derived cell-free DNA, optionally wherein the cell-free DNA comprises cell-free fetal DNA (cffDNA) or circulating tumor DNA (ctDNA).

### Claim 80

The method of any one of the preceding claims, wherein the method comprises obtaining a signal indicative of ploidy status (e.g., the allele balance signal or depth of read signal) that is derived from an embryo, optionally prior to implantation of the embryo into a womb.

### Claim 81

The method of any one of the preceding claims, wherein the method comprises obtaining a signal indicative of ploidy status (e.g., the allele balance signal or depth of read signal) that is derived from a fetus.

### Claim 82 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

A method of detecting chromosomal instability in tumor DNA, the method comprising:
determining a ploidy status according to any one of claims 32-81 for one or more chromosomal segments within a sample of genetic material that is at least partially derived from DNA originating from one or more cells known to be or suspected to be tumor cells, wherein identification of an aneuploidy status for the one or more chromosomal segments is used to indicate chromosomal instability of at least some tumor cells.

### Claim 83 (depends on 82)

The method of claim 82, wherein the sample is from a subject diagnosed with or suspected of having cancer.

### Claim 84 (depends on 82, 83)

The method of claim 82 or 83, wherein the sample comprises circulating tumor DNA.

### Claim 85 (depends on 82, 83, 84)

The method of any one of claims 82-84, wherein sequencing of normal tissue (e.g., germline tissue) from a subject from which the genetic material is obtained is used to establish a reference genetic code.

### Claim 86 (depends on 82, 83, 84)

The method of any one of the claims 82-84, wherein sequencing on tumor tissue from a subject from which the genetic material is obtained is used to establish a reference genetic code.

### Claim 87 (depends on 82, 83, 84, 85, 86)

The method of any one of claims 82-86, further comprising treating the one or more cells or a subject from which the genetic material is obtained for cancer based on whether chromosomal instability has been indicated.

### Claim 88 (depends on 87)

The method of claim 87, wherein the treatment comprises administering poly ADP ribose polymerase (PARP) inhibitors to the one or more cells or subject if chromosomal instability is indicated.

### Claim 89 (depends on 87, 88)

The method of claim 87 or 88, wherein the treatment comprises administering platinum-based chemotherapeutics to the one or more cells or subject if chromosomal instability is indicated.

### Claim 90 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

A method of detecting a de novo copy number variant (CNV) in a subject, the method comprising determining a ploidy status according to any one of claims 32-81 for a chromosomal segment, wherein the parents of the subject are euploid for the chromosomal segment, optionally wherein a de novo aneuploid (e.g., CNV) is identified in the chromosomal segment of the subject.

### Claim 91 (depends on 90)

The method of claim 90, wherein the determination of ploidy status comprises comparing the ploidy status to a reference genetic code derived from sequencing performed on one or more genetic relatives of the subject.

### Claim 92 (depends on 91)

The method of claim 91, wherein the one or more genetic relatives is a mother and/or a father.

### Claim 93 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 91, 92)

The method of claim 91 or 92, wherein the sequencing is performed with a non-error-propagating technique to provide a plurality of reads according to any one of claims 1-32.

### Claim 94 (depends on 91, 92, 93)

The method of any one of claims 91-93, wherein the sequencing is performed on cellular DNA.

### Claim 95 (depends on 90, 91, 92, 93, 94)

The method of any one of claims 90-94, further comprising determining whether the mother or father of the subject is the source of an aneuploidy.

### Claim 96 (depends on 90, 91, 92, 93, 94, 95)

The method of any one of claims 90-95, wherein the subject is an embryo.

### Claim 97 (depends on 96)

The method of claim 96, wherein the method comprises obtaining a signal indicative of ploidy status (e.g., the allele balance signal or depth of read signal) that is derived from one or more of an embryo biopsy, blastocele fluid, and cell culture medium.

### Claim 98 (depends on 97)

The method of claim 97, wherein the signal indicative of ploidy status is obtained from cell-free DNA in the culture medium.

### Claim 99 (depends on 96, 97, 98)

The method of any one of claims 96-98, further comprising selecting the embryo based on the absence or presence of an aneuploidy, optionally wherein the embryo is selected from a plurality of embryos.

### Claim 100 (depends on 99)

The method of claim 99, further comprising using the selected embryo for in vitro fertilization (IVF).

### Claim 101 (depends on 99)

The method of claim 99, further comprising disposing of the selected embryo.

### Claim 102 (depends on 99)

The method of claim 99, further comprising freezing the selected embryo.

### Claim 103 (depends on 90, 91, 92, 93, 94)

The method of any one of claims 90-94, wherein the subject is a fetus.

### Claim 104 (depends on 103)

The method of claim 103, wherein the method comprises obtaining a signal indicative of ploidy status (e.g., the allele balance signal or depth of read signal) that is derived from cell-free fetal DNA (cffDNA).

### Claim 105 (depends on 103, 104)

The method of claim 103 or 104, further comprising treating the fetus and/or the mother based on the identified absence or presence of an aneuploidy (e.g., CNV).

### Claim 106 (depends on 105)

The method of claim 105, wherein treatment comprises performing additional testing on the fetus, optionally wherein the additional testing comprises karyotyping.

### Claim 107 (depends on 105, 106)

The method of claim 105 or 106, wherein the treatment comprises terminating a pregnancy.

### Claim 108 (depends on 105, 106, 107)

The method of any one of claims 105-107, wherein the treatment comprises administering a prenatal treatment to the fetus for a disease associated with the presence of a detected aneuploidy (e.g., CNV).

### Claim 109 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

A method of screening a subject for a disease, the method comprising:
determining whether one or more genetic variants associated with the disease is present, wherein the one or more genetic variants comprises an aneuploidy (e.g., CNV) that was identified by performing the method of any one of claims 32-81 on one or more other subjects and/or an SNP that was present within a same haplotype block as the aneuploidy, optionally wherein the SNP is known to be associated with the disease.

### Claim 110 (depends on 109)

The method of claim 109, wherein the one or more genetic variants comprises the aneuploidy.

### Claim 111 (depends on 109, 110)

The method of claim 109 or 110, wherein the one or more genetic variants comprises the SNP.

### Claim 112 (depends on 109, 110, 111)

The method of any one of claims 109-111, wherein the CNV and SNP are in linkage disequilibrium.

### Claim 113 (depends on 109, 110, 111, 112)

The method of any one of claims 109-112, wherein determining whether the one or more genetic variants associated with the disease is present comprises performing sequencing on the subject, optionally wherein a portion of the genome comprising the one or more genetic variants is targeted (e.g., via a microarray).

### Claim 114 (depends on 109, 110, 111, 112, 113)

The method of any one of claims 109-113, further comprising calculating a polygenic risk score (PRS) for the disease based at least in part on the one or more genetic variants.

### Claim 115 (depends on 109, 110, 111, 112, 113, 114)

The method of any one of claims 109-114, further comprising diagnosing the subject with a disease based at least in part on the presence or absence of the one or more genetic variants or on a PRS based at least in part on the one or more genetic variants.

### Claim 116 (depends on 109, 110, 111, 112, 113, 114, 115)

The method of any one of claims 109-115, further comprising treating the subject based on the presence or absence of the one or more genetic variants.

### Claim 117

A method of phasing a germline mosaic variant in a subject, the method
comprising:
obtaining a reference genetic code comprising two phase sets, each phase set having one or more variants of interest, optionally wherein the reference genetic code is at least partially phased;
obtaining a plurality of reads sequenced using a non-error-propagating technique, wherein each read comprises at least one of the one or more variants of interest;
determining the phase alignment of the two phase sets as being in phase or out of phase based on the plurality of reads; and
identifying a haplotype comprising a chromosomal segment exhibiting an aneuploidy (e.g., CNV) based on the determined phase alignment of the two phase sets.

### Claim 118 (depends on 117)

The method of claim 117, wherein the subject is diagnosed or suspected as having a genetic disease or condition associated with the aneuploidy, optionally wherein the subject is diagnosed as having or suspected of having Noonan Syndrome or RASopathy.

### Claim 119 (depends on 117, 118)

The method of claim 117 or 118, further comprising screening gametes from the subject for the identified haplotype.

### Claim 120 (depends on 119)

The method of claim 119, further comprising selecting a gamete not having the identified haplotype for in vitro fertilization.

### Claim 121 (depends on 117, 118, 119, 120)

The method of any one of claims 117-120, further comprising screening for the haplotype in an embryo during preimplantation genetic testing.

### Claim 122 (depends on 121)

The method of claim 121, further comprising selecting an embryo based on the absence or presence of the aneuploidy, optionally wherein the embryo is selected from a plurality of embryos.

### Claim 123 (depends on 122)

The method of claim 122, further comprising using the selected embryo in in vitro fertilization (IVF).

### Claim 124 (depends on 122)

The method of claim 122, further comprising disposing of the selected embryo.

### Claim 125 (depends on 122)

The method of claim 122, further comprising freezing the selected embryo.

### Claim 126 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 117, 118, 119, 120, 121, 122, 123, 124, 125)

The method of any one of claims 117-125, wherein the aneuploidy is identified by performing the method of any one claims 32-81.
